



Journal of The Ferrata Storti Foundation

How to keep the FVIII/VWF complex in the circulation

by Cécile V. Denis and Peter J. Lenting

Received: November 11, 2021.

Accepted: November 17, 2021.

Citation: Cécile V. Denis and Peter J. Lenting. How to keep the FVIII/VWF complex in the circulation. Haematologica. 2021 Nov 25. doi: 10.3324/haematol.2021.280222. [Epub ahead of print]

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

How to keep the FVIII/VWF complex in the circulation

Cécile V. Denis¹ and Peter J. Lenting¹

¹Laboratory for Hemostasis, Inflammation & Thrombosis (HITh), Unité Mixte de Recherche (UMR)-1176, Institut National de la Santé et de la Recherche Médicale (Inserm), Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France

Authorship Contributions: CVD, and PJJ wrote the manuscript.

Correspondence:

Cécile V. Denis, Inserm U1176, 80 rue du Général Leclerc, 94270 Le Kremlin-Bicetre, France

Tel: +331-49595600; Fax: +33146719472; Email: cecile.denis@inserm.fr

Running title: Aptamer-mediated FVIII/VWF increase

Disclosure: The authors declare no conflict of interest.

Word count: 1147

References: 17

Figures: 1

VWD and hemophilia A: current treatments

Von Willebrand factor (VWF) and factor VIII (FVIII) make up for an enigmatic duo that is present in the circulation as a tightly bound complex.¹ Their individual roles in hemostasis have been well-established, and functional deficiencies of either protein is associated with severe bleeding complications, known as von Willebrand disease (VWD) and hemophilia A, respectively. Over the last several decades, the clinical management of the severe forms of these disorders predominantly relied on replacement therapy using concentrates enriched in VWF, FVIII or both. In contrast, the moderate and mild variants of VWD and hemophilia A benefited from using desmopressin, a vasopressin 2-receptor agonist that stimulates the rapid release of endothelial VWF and FVIII.^{2,3} Despite its numerous advantages (such as ease of administration, low costs, no risk of inhibitor development or of transmittable disease), desmopressin also exhibits a number of limitations. Post-treatment increases of VWF and FVIII are transient and limited by the natural short half-life (about 12 h) of the FVIII/VWF complex, and repetitive use of desmopressin results in a diminished responsiveness (tachyphylaxis) due to exhaustion of the VWF storage organelles.^{2,4} Furthermore, it has variable effectiveness in VWD-type 2A and 2M as well as in hemophilia A, while it is contra-indicated for VWD-type 2B as it may worsen the thrombocytopenia in these patients.^{2,5} Noteworthy, desmopressin is foremost an anti-diuretic, and the desmopressin-induced secretion of VWF from its storage organelles is actually an off-target effect. Finally, desmopressin use is associated with some side effects (transient headaches, facial flushing, hypotension, hyponatremia and mild tachycardia), which are generally mild and well-tolerated.^{6,7}

Increasing endogenous VWF and FVIII levels

While the abovementioned treatment options are satisfactory to some extent, there remains the need to optimize treatment. With regard to severe hemophilia A, new approaches have been approved for the clinic (*eg.* extended half-life variants of FVIII, emicizumab) or are in advanced clinical development (*eg.* fitusiran, concizumab, marstacimab, efanesoctocog alfa,

valoctocogene roxaparvovec). In contrast, few novel strategies are emerging or even appearing on the visible horizon with regard to VWD or mild hemophilia A. Interestingly, the majority of VWD and mild/moderate hemophilia A patients could already benefit from an increase in endogenous levels of the VWF/FVIII complex, as is evident from the successful use of desmopressin. It could thus be worthwhile to design approaches that aim to increase endogenous FVIII and VWF levels in a more sustainable manner compared to desmopressin. A first approach was described already twenty years ago: treatment with interleukin-11 was associated with an increase in VWF in both mouse and canine models.^{8,9} The underlying mechanism seemed to be related to an up-regulation of VWF mRNA in response to interleukin-11.⁹ However, follow-up phase II clinical studies were somewhat disappointing, as the treatment with interleukin-11 was associated with but a modest rise in VWF plasma levels (1.1-1.5-fold).^{10,11}

The anti-VWF aptamer BT200

In this issue of *Haematologica*, Kovacevic and colleagues present a new strategy that is associated with increased VWF/FVIII levels, centered around the aptamer BT200.¹² Originally, the authors developed BT200 as an antithrombotic agent to interfere with the platelet-binding activity of VWF.¹³ BT200 is a short hairpin-structured oligonucleotide consisting of the methylated nucleobases adenine, cytosine, guanine and uracil, and is an optimized derivative from the previously described aptamer ARC1779.¹⁴ Both BT200 and ARC1779 have in common that they specifically bind to the A1 domain of VWF, thereby interfering with the binding of VWF to its platelet-receptor glycoprotein Ib α (GpIb α).¹³ Preclinical studies in primates demonstrated that the improved BT200 aptamer is not only highly efficient (inhibition of VWF A1 domain activity: IC₅₀ = 70-180 nM), but also has an excellent bioavailability following subcutaneous injection (>77%) and a long half-life (>100 hours) due to its pegylated character.¹³ Studies using blood samples of stroke patients further confirmed that BT200 has a potent antithrombotic activity.¹⁵

Initial studies using ARC1779 revealed that this molecule led to an increase of VWF levels in patients with VWD-type 2B.¹⁶ These results prompted the investigators to initiate a larger first-in-human prospective phase 1 study using the improved BT200 variant, the outcomes of which is being reported in this issue.¹² In a single-dose bioavailability study, participants received 0.18 to 36 mg BT200 subcutaneously. This resulted in a dose-dependent increase in BT200 plasma concentrations, with maximal levels being around 3 µg/ml after 168 hours when given the highest dose. Increasing doses were associated with a dose-dependent occupation of the VWF A1 domain, with 75%-90% of A1 domains being occupied at doses between 12 and 24 mg. Maximal occupation was observed between one and four days after injection, after which free A1 domains gradually re-appeared to normal levels two weeks after injection. Interestingly, the administration of BT200 at these doses was associated with a 3 to 4-fold increase in VWF antigen levels. However, VWF antigen levels peaked between 7 and 14 days after injection, somewhat later compared to maximal occupation of the A1 domains. Concurrent to the increase of VWF antigen, there was also a 2.5-fold increase in FVIII activity. Of note, FVIII levels could be further increased via the administration of desmopressin, indicating that the mechanisms by which FVIII levels increase are different for BT200 and desmopressin. Indeed, BT200 appears to act by prolonging VWF half-life rather than modifying synthesis or secretion of VWF. As such, its mode of action is fundamentally different from desmopressin and interleukin-11.

In view of this listing of impressive data, it seems conceivable that BT200 is an attractive candidate to ameliorate endogenous levels of the FVWF/FVIII complex. Of course, these data represent an initial phase I study, and several issues would require additional investigations. For instance, BT200 is designed to interfere with VWF activity, and data presented in the supplementary materials show that doses inducing the highest increase in VWF/FVIII levels are also associated with prolonged closure times in the platelet function analyzer (PFA)-assay and provoke reduced platelet aggregation activity, at least during (part of) the first week.¹² It is therefore going to be key to find optimal dosing that allows increased FVIII and VWF levels, without compromising the hemostatic potential of the patient. It should

be noted that in case the activity of BT200 would need to be neutralized, the authors have already developed an efficient reversal agent, *ie* a complementary aptamer designated BT101, that specifically binds BT200 with high affinity.¹⁷

It is further interesting to speculate on the clinical application of this molecule: designed as an antithrombotic agent, which could be used for VWF-dependent thrombotic complications (arterial thrombosis, thrombotic thrombocytopenic purpura), it now also may find its use in the treatment of bleeding disorders: mild/moderate hemophilia A and certain types of VWD (Figure 1). It is unusual to find both features in a single molecule!

In conclusion, the authors present an elegant approach to ameliorate endogenous VWF and FVIII levels via a single subcutaneous administration using BT200. It is with anticipation that we look forward to additional clinical data.

References

1. Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. *Blood*. 2016;128(16):2007-2016.
2. Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). *Haemophilia*. 2008;14 Suppl 1:5-14.
3. Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. *Blood Coagul Fibrinolysis*. 2010;21(7):615-619.
4. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). *Br J Haematol*. 1992;82(1):87-93.
5. Castaman G, Tosetto A, Rodeghiero F. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. *J Thromb Haemost*. 2009;7 Suppl 1:71-74.
6. Miesbach W, Krekeler S, Duck O, et al. Clinical assessment of efficacy and safety of DDAVP. *Hamostaseologie*. 2010;30 Suppl 1:S172-175.
7. Stoof SC, Cnossen MH, de Maat MP, Leebeek FW, Kruip MJ. Side effects of desmopressin in patients with bleeding disorders. *Haemophilia*. 2016;22(1):39-45.
8. Denis CV, Kwack K, Saffaripour S, et al. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. *Blood*. 2001;97(2):465-472.
9. Olsen EH, McCain AS, Merricks EP, et al. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). *Blood*. 2003;102(2):436-441.
10. Ragni MV, Jankowitz RC, Jaworski K, Merricks EP, Kloos MT, Nichols TC. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. *Thromb Haemost*. 2011;106(4):641-645.
11. Ragni MV, Novelli EM, Murshed A, Merricks EP, Kloos MT, Nichols TC. Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A. *Thromb Haemost*. 2013;109(2):248-254.
12. Kovacevic KD, Grafeneder J, Schörghofer C, et al. The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of VWF and FVIII: a first-in-human trial. *Haematologica*. 2021;xxx.

13. Zhu S, Gilbert JC, Hatala P, et al. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer. *J Thromb Haemost.* 2020;18(5):1113-1123.
14. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. *Circulation.* 2007;116(23):2678-2686.
15. Kovacevic KD, Greisenegger S, Langer A, et al. The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. *Sci Rep.* 2021;11(1):3092.
16. Jilma-Stohlawetz P, Knobl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. *Thromb Haemost.* 2012;108(2):284-290.
17. Zhu S, Gilbert JC, Liang Z, et al. Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200. *J Thromb Haemost.* 2020;18(7):1695-1704.


Legend

Figure 1: Mode of action for BT200



BT200 is a pegylated aptamer that binds with high affinity to the platelet binding site within the VWF A1 domain. It was previously shown that BT200 interferes with VWF-dependent thrombus formation, which renders the molecule with efficient antithrombotic activity.¹³ In their study, Kovacevic and colleagues now demonstrate that BT200 also delays clearance of the VWF/FVIII complex, resulting in transient increases in plasma levels of both proteins. This approach could thus be a strategy to increase endogenous VWF/FVIII levels in patients with mild/moderate forms of VWD and hemophilia A.

BT200-mediated inhibition of VWF platelet binding-site

Anti-thrombotic action




Platelets



VWF

BT200


VWF A1 domain



Pegylated BT200 aptamer

Pro-hemostatic action

reduced clearance



increased plasma levels
endogenous VWF/FVIII complex